Cell Disruption Ultrasonic Disruption Patents: Leaders & Trends 2026
Cell Disruption and Ultrasonic Disruption Patents: Who Holds the Claims
Filing is concentrated but not locked up. the ranked leader holds 24 records and the top 5 combined account for 28.2% of all 277 records in scope — a strong front but a long tail behind it. Volume rose from 6 records in 2017 to a peak of 13 in 2023. The 2021-to-2024 span shows the clearest complete-year signal: 2 filings growing to 5, a 150% increase. 2025 and 2026 figures will continue to rise as publications catch up.
- 1GENENTECH INC24
- 2QVELLA CORP19
- 3COVARIS INC13
- 4BATTELLE MEMORIAL INST12
- 5DNA GENOTEK10
See the full cell disruption ultrasonic disruption analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
Who holds the most patents in cell disruption and ultrasonic disruption technology?
The ranked leader in this dataset holds 24 of the 277 records in scope, notably ahead of the fifth-placed assignee at 10 records. Even so, the top 5 assignees combined account for only 28.2% of all records, meaning no single organisation controls the field. The ranking itself covers 100 companies counted in records, not a hand-picked top tier, so the picture includes a long tail of single- and few-filing entrants alongside the leader.
Is patent filing in ultrasonic cell disruption growing or slowing?
Filings grew from 2 in 2021 to 5 in 2024, a 150% increase over that three-year window, with a peak of 13 records in 2023. Because publication typically lags filing by around 18 months, the 2025 and 2026 figures in any trend chart are still incomplete and should not be read as a slowdown. Based on the complete-year data through 2024, the trend is upward rather than flat.
What technology areas do these patents actually claim?
The overwhelming majority, 87.4% of the 277 records, fall under C12N, the class covering microorganisms and genetic engineering, with bioreactor apparatus (C12M) at 37.2% and fermentation/enzymatic synthesis (C12P) at 30.7%. Chemical and physical process claims tied more directly to the ultrasonic mechanism (B01J) appear in only 14.8% of records. This means most claim language centres on what the disruption achieves biologically rather than on the acoustic engineering itself.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Cell Disruption Ultrasonic Disruption covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.